Liquid-cooled, massively overclockable, and packing a glorious side-panel display, MSI’s GeForce RTX 5090 Lightning Z ...

It's been a while since we've tested a laptop, but CHUWI sent us their latest CoreBook AirPlay 16 laptop for review. It's powered by a mid-range AMD Ryzen ...

CSL shares have fallen almost 40% in 2025. Investors are now asking if the worst is already behind the stock. CSL shares fell nearly 40% in 2025 due to underwhelming profit guidance, elevated costs, ...

The College Swimming League (CSL), a revolutionary sports enterprise, today unveiled its plans to fundamentally reimagine college swimming. Founded by Robert Kent and Kyle Sockwell, with support from ...

CSL shares remain down 35.2% over the past year, impacted by concerns over vaccine sales and strategic changes. Analyst John Athanasiou from Red Leaf Securities suggests CSL shares are oversold, ...

Some of Australia’s largest blue-chip investors have been caught on the wrong side of one of the year’s most crowded trades after piling into CSL as an alternative to holding a big position in ...

CSL Limited (OTCQX:CSLLY) (OTCQX:CMXHF), an Australian biotech focused on developing vaccines and blood-derived therapies, on Tuesday announced plans to invest approximately $1.5B in the U.S. over the ...

CSL Ltd., the world’s second-biggest maker of flu shots, forecast a US vaccination rebound as health groups counter misinformation and rising illness rates revive concern about prevention. A recovery ...

US vaccination forecast leads to fall in stock price, while board survives spill in ‘second strike’ over pay concerns at AGM Follow our Australia news live blog for latest updates Get our breaking ...

SYDNEY, Oct 28 (Reuters) - Australian biotech CSL (CSL.AX), opens new tab has cut its profit outlook and delayed plans to spin off its vaccine division, blaming an unprecedented fall in U.S. flu ...

A strike is when more than 25 per cent of shareholders are against a company proposal, in this case executive pay, paving the way for a second ballot on whether to spill the board. Shareholders have ...

SYDNEY (Reuters) -Australian biotech CSL has cut its profit outlook and delayed plans to spin off its vaccine division, blaming an unprecedented fall in U.S. flu immunisation rates, which knocked its ...